Cite
HARVARD Citation
Ott, P. et al. (n.d.). 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. European journal of cancer. 51 (3), pp. S102-. [Online].